Form 4 for DNLI Denali Therapeutics Inc.

Accepted 2021-10-06 00:00:00 ET · period of report 2021-10-04 · accession 0001714899-21-000094 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MI	2021-10-06	2021-10-04	DNLI	Schuth Alexander O.	COO, Sec	S - Sale	$50.56	-10.0K	477.1K	-2%	-$505.6K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-10-04	S	D	4,006	$51.04	473,083	I See footnote	—	—	(F5) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $50.64 to $51.3350 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Restated to accurately report holdings that were misallocated in the Reporting Person's previous Form 4. (F4) The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.
2	Common	Common Stock	2021-10-04	S	D	5,994	$50.24	477,089	I See footnote	—	—	(F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $49.6350 to $50.6275 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Restated to accurately report holdings that were misallocated in the Reporting Person's previous Form 4. (F4) The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.